The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome
Multiple sclerosis (MS) is a clinically heterogenous disease. Currently, we cannot identify patients with more active disease who may potentially benefit from earlier interventions. Previous data from our lab identified the CXCL13 index (I<sub>CXCL13</sub>), a measure of intrathecal prod...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/13/11050 |
| _version_ | 1797591474751143936 |
|---|---|
| author | Steven C. Pike Francesca Gilli Andrew R. Pachner |
| author_facet | Steven C. Pike Francesca Gilli Andrew R. Pachner |
| author_sort | Steven C. Pike |
| collection | DOAJ |
| description | Multiple sclerosis (MS) is a clinically heterogenous disease. Currently, we cannot identify patients with more active disease who may potentially benefit from earlier interventions. Previous data from our lab identified the CXCL13 index (I<sub>CXCL13</sub>), a measure of intrathecal production of CXCL13, as a potential biomarker to predict future disease activity in MS patients two years after diagnosis. Patients with clinically isolated syndrome (CIS) or radiologically isolated syndrome (RIS) underwent a lumbar puncture and blood draw, and the I<sub>CXCL13</sub> was determined. They were then followed for at least 5 years for MS activity. Patients with high I<sub>CXCL13</sub> were more likely to convert to clinically definite MS (82.4%) compared to those with low I<sub>CXCL13</sub> (10.0%). The data presented below demonstrate that this predictive ability holds true in CIS and RIS patients, and for at least five years compared to our initial two-year follow-up study. These data support the concept that I<sub>CXCL13</sub> has the potential to be used to guide immunomodulatory therapy in MS. |
| first_indexed | 2024-03-11T01:37:57Z |
| format | Article |
| id | doaj.art-3c758ddc3f294e219c93b7d3acc1d8cc |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T01:37:57Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-3c758ddc3f294e219c93b7d3acc1d8cc2023-11-18T16:47:24ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-07-0124131105010.3390/ijms241311050The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated SyndromeSteven C. Pike0Francesca Gilli1Andrew R. Pachner2Department of Neurology, Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USADepartment of Neurology, Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USADepartment of Neurology, Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USAMultiple sclerosis (MS) is a clinically heterogenous disease. Currently, we cannot identify patients with more active disease who may potentially benefit from earlier interventions. Previous data from our lab identified the CXCL13 index (I<sub>CXCL13</sub>), a measure of intrathecal production of CXCL13, as a potential biomarker to predict future disease activity in MS patients two years after diagnosis. Patients with clinically isolated syndrome (CIS) or radiologically isolated syndrome (RIS) underwent a lumbar puncture and blood draw, and the I<sub>CXCL13</sub> was determined. They were then followed for at least 5 years for MS activity. Patients with high I<sub>CXCL13</sub> were more likely to convert to clinically definite MS (82.4%) compared to those with low I<sub>CXCL13</sub> (10.0%). The data presented below demonstrate that this predictive ability holds true in CIS and RIS patients, and for at least five years compared to our initial two-year follow-up study. These data support the concept that I<sub>CXCL13</sub> has the potential to be used to guide immunomodulatory therapy in MS.https://www.mdpi.com/1422-0067/24/13/11050CXCL13B cellmultiple sclerosisclinically isolated syndromeradiologically isolated syndrome biomarkerinitial clinical demyelinating event |
| spellingShingle | Steven C. Pike Francesca Gilli Andrew R. Pachner The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome International Journal of Molecular Sciences CXCL13 B cell multiple sclerosis clinically isolated syndrome radiologically isolated syndrome biomarker initial clinical demyelinating event |
| title | The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome |
| title_full | The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome |
| title_fullStr | The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome |
| title_full_unstemmed | The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome |
| title_short | The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome |
| title_sort | cxcl13 index as a predictive biomarker for activity in clinically isolated syndrome |
| topic | CXCL13 B cell multiple sclerosis clinically isolated syndrome radiologically isolated syndrome biomarker initial clinical demyelinating event |
| url | https://www.mdpi.com/1422-0067/24/13/11050 |
| work_keys_str_mv | AT stevencpike thecxcl13indexasapredictivebiomarkerforactivityinclinicallyisolatedsyndrome AT francescagilli thecxcl13indexasapredictivebiomarkerforactivityinclinicallyisolatedsyndrome AT andrewrpachner thecxcl13indexasapredictivebiomarkerforactivityinclinicallyisolatedsyndrome AT stevencpike cxcl13indexasapredictivebiomarkerforactivityinclinicallyisolatedsyndrome AT francescagilli cxcl13indexasapredictivebiomarkerforactivityinclinicallyisolatedsyndrome AT andrewrpachner cxcl13indexasapredictivebiomarkerforactivityinclinicallyisolatedsyndrome |